IL6R and rheumatoid arthritis: Currently, four different types of bDMARDs—TNF inhibitors, anti-IL-6R inhibitors, T cell costimulatory inhibitor (CTLA-Ig), and anti-CD20 Ab—have been approved for RA therapy [29,30,31].